Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir (PF-07817883) Dose-Ranging Study in Non-Hospitalized COVID-19
NCT05799495Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5. Started May 2023; status: completed.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05799495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799495.